RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

Yes, looks like a reverse split (325 to 1) that will reduce the share count down to 70 mil shares. The stockholder's meeting is Aug 16, which should be in the general timeframe of the Phase 2 clinical trial results, so good timing. The best time for a reverse split is when a company's prospects are clearly improving, which helps to maintain the share price at the new higher level -


http://www.sec.gov/Archives/edgar/data/849636/000149315216010598/pre14a.htm


>>> A Special Meeting of Stockholders of RespireRx Pharmaceuticals Inc. will be held at the New York offices of the Company’s legal counsel, Drinker Biddle and Reath LLP, located at 1177 Avenue of the Americas, 41st Floor, New York, New York 10036-2714 on August 16, 2016 at 12:00 p.m., Eastern time, to approve an amendment to our second restated certificate of incorporation (i) to effect, at the discretion of our Board of Directors, a three hundred twenty five-to-one (325 to 1) reverse stock split of all of the outstanding shares of our common stock, par value $0.001 per share, and (ii) to set the number of the company’s authorized shares of stock at 70,000,000 shares consisting of 65,000,000 shares designated as common stock, par value $0.001 per share, and 5,000,000 shares designated as preferred stock. Attached to this notice is a proxy statement setting forth information with respect to the proposal and certain other information. <<<